Chadds Ford-based Endo Pharmaceuticals said there will be a "short-term supply constraint" of its pain pill, Opana ER.
The cause is a temporary shutdown of a manufacturing plant run by Novartis Consumer Health in Lincoln, Neb. Endo said that production was suspended to enable Novartis to make "certain manufacturing process improvements," involving packaging.
Novartis said on Sunday that it was halting operations and shipments at the Nebraska plant, and it is recalling various products such as Excedrin, NoDoz and Bufferin. Novartis said it will take a $120 million charge in the fourth quarter in connection with the recalls and manfacturing changes.
Endo said the disruption in Opana production is "not related to the efficacy or safety" of its products. In the meantime, the company is planning to ramp up production at other manufacturing plants.